Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Management of diabetic dyslipidemia: doing the right thing

Nature Clinical Practice Endocrinology & Metabolism volume 2, pages 550–551 (2006)Cite this article

Access through your institution
Buy or subscribe

boxed-textCosta J et al. (2006) Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomized controlled trials. BMJ 332: 1115–1124

Background

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Keech A et al. (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9,795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366: 1849–1861

    Article  CAS  Google Scholar 

  2. Canner PL et al. (2005) Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 95: 254–257

    Article  CAS  Google Scholar 

  3. National Diabetes Data Group (Eds; 1995) Diabetes in America, edn 2. Bethesda, MD: NIH National Institute of Diabetes and Digestive and Kidney Diseases

  4. Kennedy AG et al. (2005) The challenge of achieving national cholesterol goals in patients with diabetes. Diabetes Care 28: 1029–1034

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. the Director of the Metabolism Section of Cardiovascular Genetics, and Associate Professor at the University of Utah School of Medicine, Salt Lake City, UT, USA

    Eliot A Brinton

Authors
  1. Eliot A Brinton
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Eliot A Brinton.

Ethics declarations

Competing interests

Dr Brinton has received grant support for research activities from AstraZeneca, Kos, Merck, Novartis, Pfizer, Daiichi-Sankyo, Sanofi-Aventis and Takeda Pharmaceuticals. He is on an advisory board and/or speakers' bureau for Abbott, Amylin, AstraZeneca, Atherotech, Bristol-Myers Squibb, GlaxoSmithKline, Kos, Eli Lilly, Merck, Novartis, Organon, Pfizer, Proctor & Gamble, Reliant, Daiichi-Sankyo, Sanofi-Aventis, Takeda and Wyeth-Ayerst Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brinton, E. Management of diabetic dyslipidemia: doing the right thing. Nat Rev Endocrinol 2, 550–551 (2006). https://doi.org/10.1038/ncpendmet0293

Download citation

  • Received:

  • Accepted:

  • Issue date:

  • DOI: https://doi.org/10.1038/ncpendmet0293

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing